Photo from wikipedia
Long‐term treatment effect studies in large female Fabry patient groups are challenging to design because of phenotype heterogeneity and lack of appropriate comparison groups, and have not been reported. We… Click to show full abstract
Long‐term treatment effect studies in large female Fabry patient groups are challenging to design because of phenotype heterogeneity and lack of appropriate comparison groups, and have not been reported. We compared long‐term cardiomyopathy and kidney function outcomes after agalsidase beta treatment with preceding treatment‐naive outcomes.
Keywords:
cardiomyopathy kidney;
treatment;
agalsidase beta;
female fabry;
kidney function
Journal Title: ESC Heart Failure
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: ESC Heart Failure
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!